72 related articles for article (PubMed ID: 28009975)
1. PARP Inhibitors: Staying on Target?
Doig CL; Lavery GG
Cell Chem Biol; 2016 Dec; 23(12):1442-1443. PubMed ID: 28009975
[TBL] [Abstract][Full Text] [Related]
2. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
Schreiber V; Illuzzi G; Héberlé E; Dantzer F
Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
[TBL] [Abstract][Full Text] [Related]
3. Poly(ADP-ribosyl)ation polymerases: mechanism and new target of anticancer therapy.
Heitz F; Harter P; Ewald-Riegler N; Papsdorf M; Kommoss S; du Bois A
Expert Rev Anticancer Ther; 2010 Jul; 10(7):1125-36. PubMed ID: 20645701
[TBL] [Abstract][Full Text] [Related]
4. Platinated benzonaphthyridone is a stronger inhibitor of poly(ADP-ribose) polymerase-1 and a more potent anticancer agent than is the parent inhibitor.
Wang B; Qian H; Yiu SM; Sun J; Zhu G
Eur J Med Chem; 2014 Jan; 71():366-73. PubMed ID: 24361480
[TBL] [Abstract][Full Text] [Related]
5. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
6. An enzymatic assay for poly(ADP-ribose) polymerase-1 (PARP-1) via the chemical quantitation of NAD(+): application to the high-throughput screening of small molecules as potential inhibitors.
Putt KS; Hergenrother PJ
Anal Biochem; 2004 Mar; 326(1):78-86. PubMed ID: 14769338
[TBL] [Abstract][Full Text] [Related]
7. PARP inhibitors: polypharmacology versus selective inhibition.
Ekblad T; Camaioni E; Schüler H; Macchiarulo A
FEBS J; 2013 Aug; 280(15):3563-75. PubMed ID: 23601167
[TBL] [Abstract][Full Text] [Related]
8. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
9. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
Drew Y; Plummer R
Curr Opin Obstet Gynecol; 2010 Feb; 22(1):67-71. PubMed ID: 19934756
[TBL] [Abstract][Full Text] [Related]
10. Discussion of PARP inhibitors in cancer therapy.
Wielgos M; Yang ES
Pharm Pat Anal; 2013 Nov; 2(6):755-66. PubMed ID: 24237241
[TBL] [Abstract][Full Text] [Related]
11. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis.
Tentori L; Lacal PM; Muzi A; Dorio AS; Leonetti C; Scarsella M; Ruffini F; Xu W; Min W; Stoppacciaro A; Colarossi C; Wang ZQ; Zhang J; Graziani G
Eur J Cancer; 2007 Sep; 43(14):2124-33. PubMed ID: 17714938
[TBL] [Abstract][Full Text] [Related]
12. Multiple roles for poly(ADP-ribose)polymerase-1 in neurological disease.
Kauppinen TM
Neurochem Int; 2007 Jun; 50(7-8):954-8. PubMed ID: 17222947
[TBL] [Abstract][Full Text] [Related]
13. An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors.
Liu X; Palma J; Kinders R; Shi Y; Donawho C; Ellis PA; Rodriguez LE; Colon-Lopez M; Saltarelli M; LeBlond D; Lin CT; Frost DJ; Luo Y; Giranda VL
Anal Biochem; 2008 Oct; 381(2):240-7. PubMed ID: 18674509
[TBL] [Abstract][Full Text] [Related]
14. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
15. Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
D'Onofrio G; Tramontano F; Dorio AS; Muzi A; Maselli V; Fulgione D; Graziani G; Malanga M; Quesada P
Biochem Pharmacol; 2011 Jan; 81(2):194-202. PubMed ID: 20875401
[TBL] [Abstract][Full Text] [Related]
16. Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Leprdb/db mice.
Szabó C; Biser A; Benko R; Böttinger E; Suszták K
Diabetes; 2006 Nov; 55(11):3004-12. PubMed ID: 17065336
[TBL] [Abstract][Full Text] [Related]
17. Expression of human poly (ADP-ribose) polymerase 1 in Saccharomyces cerevisiae: Effect on survival, homologous recombination and identification of genes involved in intracellular localization.
La Ferla M; Mercatanti A; Rocchi G; Lodovichi S; Cervelli T; Pignata L; Caligo MA; Galli A
Mutat Res; 2015 Apr; 774():14-24. PubMed ID: 25779917
[TBL] [Abstract][Full Text] [Related]
18. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology.
Ratnam K; Low JA
Clin Cancer Res; 2007 Mar; 13(5):1383-8. PubMed ID: 17332279
[TBL] [Abstract][Full Text] [Related]
19. C12orf48, termed PARP-1 binding protein, enhances poly(ADP-ribose) polymerase-1 (PARP-1) activity and protects pancreatic cancer cells from DNA damage.
Piao L; Nakagawa H; Ueda K; Chung S; Kashiwaya K; Eguchi H; Ohigashi H; Ishikawa O; Daigo Y; Matsuda K; Nakamura Y
Genes Chromosomes Cancer; 2011 Jan; 50(1):13-24. PubMed ID: 20931645
[TBL] [Abstract][Full Text] [Related]
20. Multi-targeted organometallic ruthenium(II)-arene anticancer complexes bearing inhibitors of poly(ADP-ribose) polymerase-1: A strategy to improve cytotoxicity.
Wang Z; Qian H; Yiu SM; Sun J; Zhu G
J Inorg Biochem; 2014 Feb; 131():47-55. PubMed ID: 24239912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
